Pfizer adds a second berobenatide (PF-08653944) Phase 3 — obesity monotherapy, n=954 — extending the Phase 3 program it quietly began with the obesity+T2D study in February. — 2 trials with material updates.

Competitive Intelligence · Obesity & T2D

Tuesday, May 19, 2026

Pfizer adds a second berobenatide (PF-08653944) Phase 3 — obesity monotherapy, n=954 — extending the Phase 3 program it quietly began with the obesity+T2D study in February.

Key Signals · 2 trials updated

  • Pfizer berobenatide Phase 3 obesity monotherapy [NCT07595549] first-posted today: n=954, NOT_YET_RECRUITING, starts 2026-06-02, PCD 2028-05-04. Pairs with already-recruiting obesity+T2D study NCT07400653 (n=999, started 2026-02-24) — Pfizer's berobenatide Phase 3 pair now complete in the registry.
  • Novo Nordisk semaglutide Phase 3 [NCT06041217] (n=242) posted full results: semaglutide 2.4mg −12.2% vs placebo −2.2% body weight at week 44; ≥5% responders 128 vs 19; SAEs 14 vs 3. Confirmatory of STEP-class effect sizes.

Material updates — 2026-05-18 → 2026-05-19

Pfizer berobenatide — Phase 3 pair now complete

  • NCT07595549 — berobenatide (PF-08653944) Phase 3 in obesity/overweight, n=954, NOT_YET_RECRUITING, starts 2026-06-02, PCD 2028-05-04. StudyFirstPostDate = 2026-05-19 (genuine first registry post today).
  • Pairs with NCT07400653 — berobenatide Phase 3 in obesity + T2D, n=999, RECRUITING since 2026-02-24 (first-posted 2026-02-10, not a new event today; included here only as paired context).
  • Read: Pfizer's berobenatide Phase 3 program is now visible as a pair (~1,950 patients), spanning monotherapy obesity and obesity+T2D — the standard sponsor blueprint for a chronic-weight-management label. PCDs Oct 2027 (T2D) and May 2028 (monotherapy). This is Pfizer's first registry-visible serious Phase 3 obesity push since the danuglipron program was discontinued in 2024.
  • Not flagged today (already-known recruiting trials, no material change visible on triage fields): Pfizer/Metsera MET097 [NCT07311850] (recruiting since Dec 2025), Novo AMAZE 12 [NCT07503210] (recruiting since Apr 2026), Novo AMAZE 2 [NCT07533175] (recruiting since Apr 2026), Novo NNC0662-0419 Phase 2 [NCT07415954] (recruiting since early May 2026), Novo CagriSema CVOT REDEFINE 3 [NCT05669755] (admin update on a 2023 trial), Lilly orforglipron pediatric [NCT06672549] and SURMOUNT-ADOLESCENTS-2 [NCT06439277] (both running since 2024). The 2026-05-18/19 LastUpdatePostDate bumps on these records reflect routine administrative edits, not material protocol or status changes.

Novo Nordisk semaglutide Phase 3 — results posted

  • NCT06041217 — semaglutide 2.4 mg vs. placebo, n=242, COMPLETED 2025-05-07. Results posted (LastUpdate 2026-05-18, HasResults=true).
  • Topline (week 44):

- Primary: body weight change −12.2% (sema) vs. −2.2% (placebo)

- ≥5% weight loss responders: 128 vs. 19 participants

- ≥10% responders: 96 vs. 9

- Waist circumference: −9.1 cm vs. −2.4 cm

- HbA1c: −0.4% vs. 0.0%

- SAEs: 14 vs. 3 (consistent with known semaglutide safety profile)

  • Read: Confirmatory rather than novel — effect sizes align with the STEP-1 (~14.9%) and STEP-2 (~9.6%, T2D) range. Modest n=242 limits market-moving impact. Useful as a registry reference but does not change competitive positioning.

Audit note

Today's report applies the change-classification step added to prompts/monitor.txt: only trials with StudyFirstPostDate in the 24h window, a verifiable status/PCD/enrollment delta, or newly-posted results are promoted. The prior unflagged set (7 trials with LastUpdatePostDate bumps but no material delta) is excluded as noise.

Generated by Claude Code + ClinicalTrials.gov MCP · clinicaltrials.gov
Rendered: 2026-05-20T00:10:16.206Z